Clinical trials sponsored by Bristol-Myers Squibb

Phase breakdown

Conditions studied

Recruiting trials led by Bristol-Myers Squibb

• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 144 locations
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 159 locations
• A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea
  NCT06073873 · Phase: Not specified · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
  NCT05489705 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 101 locations
• A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
  NCT05744466 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
  NCT06701513 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 48 locations
• A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
  NCT05076175 · Phase: Phase 2, Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 90 locations
• A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT07680764 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 71 locations
• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
  NCT07175285 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female) · 66 locations
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 94 locations
• A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
  NCT06764771 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
  NCT06730750 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
  NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 57 locations
• A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
  NCT07412704 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 39 locations
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 295 locations
• A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
  NCT06855771 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 70 locations
• A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
  NCT05953402 · Phase: Not specified · Ages: No age limits stated · Sex: Female · 1 location
• A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
  NCT06382987 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
  NCT05170126 · Phase: Not specified · Ages: No age limits stated · Sex: Female · 3 locations
• A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06067841 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 15 locations
• A Study to Assess Deucravacitinib Safety in Pregnancy
  NCT07017699 · Phase: Not specified · Ages: No age limits stated · Sex: Female · 1 location
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
  NCT06929273 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 182 locations
• A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
  NCT07325136 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
  NCT06875960 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 4 locations
• A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  NCT06481306 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
  NCT07361497 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 259 locations
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
  NCT06947941 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 44 locations
• A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
  NCT04772079 · Phase: Phase 3 · Ages: 4 Years to 18 Years · Sex: All (male and female) · 65 locations
• A Study to Evaluate the Effect of KarXT on Urological Safety
  NCT07221877 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 13 locations
• A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
  NCT07140913 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 104 locations
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
  NCT06976216 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · 119 locations
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · 127 locations
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
  NCT06951698 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 74 locations
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
  NCT06951711 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 85 locations
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
  NCT07288567 · Phase: Phase 3 · Ages: 13 Years to 17 Years · Sex: All (male and female) · 38 locations
• A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
  NCT06882785 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 56 locations
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 279 locations
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
  NCT06979453 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 132 locations
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 252 locations
• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
  NCT07221357 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 283 locations
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
  NCT07171983 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 9 locations
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
  NCT06476808 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
  NCT07061288 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 8 locations
• An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany
  NCT06169956 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
  NCT07256015 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
  NCT07379827 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 55 locations
• Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
  NCT07271069 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
  NCT07101094 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
  NCT07116967 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · 402 locations
• Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
  NCT06258668 · Phase: Not specified · Ages: 19 Years and older · Sex: All (male and female) · 2 locations
• Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
  NCT07732907 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
  NCT07100080 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 186 locations
• Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
  NCT06408259 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · 33 locations

Common questions

How many trials is Bristol-Myers Squibb recruiting for?

Bristol-Myers Squibb is the lead sponsor of 54 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.